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ABSTRACT
p73, the p53 homologue, exists as a transactivation-
domain-proficient TAp73 or deficient deltaN(DN)p73
form. Expectedly, the oncogenic DNp73 that is cap-
able of inactivating both TAp73 and p53 function, is
over-expressed in cancers. However, the role of
TAp73, which exhibits tumour-suppressive proper-
ties in gain or loss of function models, in human
cancers where it is hyper-expressed is unclear. We
demonstrate here that both TAp73 and DNp73 are
able to specifically transactivate the expression of
the anti-apoptotic member of the caspase family,
caspase-2S. Neither p53 nor TAp63 has this proper-
ty, and only the p73b form, but not the p73a form,
has this competency. Caspase-2 promoter anal-
ysis revealed that a non-canonical, 18bp GC-rich
Sp-1-binding site-containing region is essential for
p73b-mediated activation. However, mutating the
Sp-1-binding site or silencing Sp-1 expression did
not affect p73b’s transactivation ability. In vitro
DNA binding and in vivo chromatin immunoprecipi-
tation assays indicated that p73b is capable of
directly binding to this region, and consistently,
DNA binding p73 mutant was unable to transactivate
caspase-2S. Finally, DNp73b over-expression in neu-
roblastoma cells led to resistance to cell death, and
concomitantly to elevated levels of caspase-2S.
Silencing p73 expression in these cells led to reduc-
tion of caspase-2S expression and increased cell
death. Together, the data identifies caspase-2S as
a novel transcriptional target common to both
TAp73 and DNp73, and raises the possibility that
TAp73 may be over-expressed in cancers to pro-
mote survival.
INTRODUCTION
p73 is a member of the p53 family of transcription factors,
existing as numerous NH2- and COOH-terminal isoforms
(1,2) The NH2-terminal variant, known as the deltaNp73
(DNp73), is generated from an internal intronic promoter
and lacks the NH2-terminal transactivation (TA) domain,
and hence, has been suggested to bind to and counter the
tumour-suppressive properties of the TA proﬁcient full-
length TAp73 forms (3,4). However, some reports have
suggested that DNp73 have some ability to transactivate
target genes due to the presence of a second TA domain,
which includes the PxxP motif (5). The COOH-terminal
variants arise due to alternate splicing resulting in multiple
isoforms that exhibit varying degrees of TApotential (6,7).
The longest isoform, the TAp73a, generally shows weaker
activity than TAp73b and TAp73g that exhibit stronger
TA potential (7,8). Hitherto, it has been classically
thought that the TAp73 forms primarily function as
tumour suppressors, albeit weaker than p53 itself, whereas
the DNp73 forms act as oncogenes, as has been demon-
strated by genetic, over-expression and other in vitro stu-
dies (3,9,10).
However, clinical reports analysing p73 expression pro-
ﬁle have highlighted a complicating scenario. Not only are
the DNp73 forms over-expressed as expected, but also the
TAp73 forms are over-expressed in a multitude of human
cancers (6,11–17). It was shown that one-third of tumours
that over-express DNp73 forms also exhibited concomi-
tant up-regulation of the antagonistic TAp73 (12).
Although co-over-expression of DNp73 with TAp73
may nullify the tumour-suppressive properties of the
latter in human tumours, it is still unclear why there is a
need for TAp73 forms to be over-expressed at all. Recent
data from others and us have provided evidence for a role
for TAp73 in supporting cellular growth, and hence, in
tumour development. Ectopic expression of TAp73 was
shown to support cellular survival under deﬁned
*To whom correspondence should be addressed. Tel: +65 6436 8349; Fax: +65 6226 5694; Email: cmrksb@nccs.com.sg
 2008 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.conditions, and conversely, absence of p73 led to reduced
proliferation, through the regulation of AP-1 activity (18).
Consistently, TAp73 expression was also found to lead to
the activation of the promoter of gastrin, a peptide hor-
mone that is important in determining the progression of a
number of human malignancies, and a strong correlation
was noted between gastrin and TAp73 levels in gastric
cancers (19). In addition, over-expression of both TAp73
and DNp73 seen in upper gastrointestinal carcinomas cor-
related with TCF-dependent transcriptional activation
and the up-regulation of b-catenin in gastrointestinal
cells, implying a tumour-promoting role for combined
expression of TAp73 and DNp73 (20). Finally, TAp73
was seen to negate p53-mediated suppression of human
telomerase expression, suggesting a contributory role for
TAp73 in carcinogenesis (21). These data therefore suggest
that TAp73 forms may support cellular survival, besides
their classical roles as tumour suppressors, though the
exact context in which these properties are exhibited is
unclear.
Nevertheless, as with p53, p73 forms have also been
shown to regulate apoptosis, a critical process suppressing
tumourigenesis. TAp73 has been shown to induce the
expression of genes like puma and scotin amongst others
(22), and absence of the anti-apoptotic DNp73 was shown
to lead to massive apoptosis in the developing mouse brain
(23). However, whether the core component of the apo-
ptotic machinery—the proteolytic system involving a
family of proteases known as caspases (24)—is regulated
by p73 members is unclear. There are 14 members in the
caspase family, which can be generally grouped into two
main groups according to their functions: those involved
in cytokine processing (caspase-1, -4, -5, -11 to -14) and
those in apoptosis (caspase-2, -3, -6 to -10) (25). Of the
apoptotic caspases studied, the function and regulation of
caspase-2, -8 and -9 have been the best characterized. Of
these, caspase-2 is interesting as it exists as two distinct
isoforms with opposing functions: the long caspase-2L
form induces cell death, while the short caspase-2S isoform
inhibits cell death upon over-expression (26,27). The
dominant caspase-2L form is expressed in most tissues,
whereas caspase-2S is preferentially expressed in brain
and skeletal muscles (27). The two mRNAs diﬀer at
their 50-end, suggesting the existence of distinct transcrip-
tional start sites (28). The 50 RT–RACE and RNase pro-
tection assays showed that the main transcription start site
of caspase-2S diﬀers from the transcription start site of
caspase-2L. Caspase-2S transcription initiates within
intron 1 of the caspase-2 gene and the presence of a
TATA box in caspase-2S promoter suggest that under spe-
ciﬁc conditions, caspase-2S expression can be up-regulated
(28). In addition, caspase-2S isoform is produced
by the insertion of a 61-bp exon at the 30-end of the
caspase-2 pre-mRNA, which introduces a premature
stop codon (27).
Since TAp73 appears to regulate both apoptosis and
also support cellular survival, we explored the possibility
that it would diﬀerentially regulate caspase expression.
Interestingly, we found that both TA73b and DN73b iso-
forms were able to induce the expression of caspase-2S,
but not of the other caspases tested. This induction is
dependent on a unique 18-bp p73b-recognition sequence
on the caspase-2S promoter to which both TA73b and
DN73b bind directly in vivo and in vitro. Consistently,
over-expression of DN73b in neuroblastoma cells led to
elevated levels of caspase-2S expression and these cells
were resistant to cell death induced by several means.
The data together identify caspase-2S as a novel target
of both TA73b and DN73b isoforms, suggesting a role
for them in promoting cellular survival.
MATERIALS AND METHODS
Cells,plasmids and transfections
The p53 null H1299 cells and Saos-2 cells inducibly expres-
sing TAp73b have been described (18). SH-SY5Y neuro-
blastoma cells were transfected with pcDNA or DNp73b
and selected on G418 to generate stable transfectants.
Saos2-TAp73b inducible cells were maintained in
DMEM supplemented with 10% tetracycline free FBS,
and TAp73b was induced by addition of 2mM doxocycline
prior to harvesting at the indicated time points.
The 2 10
5 cells (in 6-well dishes) were used for trans-
fection experiments using Lipofectamine PLUS-Reagent
according to manufacturer’s instructions (Invitrogen,
Carlsbad, CA, USA). H1299 cells were transiently trans-
fected with various plasmids, and collected 36 or 24h later
for RT–PCR or luciferase analysis, respectively. siRNA
was transfected at 3mg per well using RNAifect (Qiagen,
Valencia, CA, USA), as per manufacturer’s protocols.
The pCDNA3-based expression plasmids for p53,
TAp63a, TAp63b, TAp73a, TAp73b, TAp73b-292,
DNp73b and DNp73b-292 have been described (21).
TAp63a and TAp63b expression plasmids are gifts from
Dr Giovanni Blandino (Regina Elena Cancer Institute,
Rome) and Dr Massimo Broggini (Mario Negri Institute,
Milan). The Sp-1 cDNA was a gift from Dr Robert Tjian
(University of California, Berkerly, USA) (29). PCM2,
Del1, Del2, Del3 and Del4 caspase-2 promoter-luciferase
constructshavebeendescribed(28).Site-directedmutagen-
esis was performed as per manufacturer’s instructions
(Stratagene, La Jolla, CA, USA) using the Del4 promoter
to generate Del4 truncations Del4.1, Del4.2 and Del4.3 by
PCR cloning, using primers as follows: Del4.1-for: 50AA
AAGGTACCAGCCTGACTCCGCGCAAGG30, Del4.2-
for: 50AAAAGGTACCTCCTTATGAGGGAAACTAT
AA30, Del4.3-for: 50AAAAGGTACCGTCTCTCGTGG
GAAAAGACTGGC30 and a common reverse primer
Del4-rev: 50ACTTAGATCGCAGATCTCGAGTCGAT
AC30. Sp-1 siRNA was purchased from Santa Cruz Bio-
technology Inc (Santa Cruz, CA, USA), and p73 and the
control siRNA were purchased from Qiagen. The sequence
of p73 siRNA is as follows: 50- - - AAGGCAATAATCT
CTCGCAGT - - -30, and targets both TAp73 and DNp73
forms.
Celldeathassays
SH-SY5Y cells stably expressing pCDNA or DNp73b
were seeded in triplicates in 6-well plates and serum-
starved in serum-free DMEM for indicated time periods
before harvesting for sub-G1 analysis. Cells were ﬁxed in
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ed with RNase A for 20min before addition of 5mg/ml PI
and analysed by BD Biosciences FACScalibur (Mountain
View, CA, USA). Similarly, cells were treated with 20mM
cisplatin for 24h or serum-starved for 48h, and analysed
for cell viability by their ability to exclude propidium
iodide, by ﬂow cytometry. For siRNA experiments,
siRNA was transfected 24h prior to serum-starvation for
a further 48h before analysis of cell death.
Luciferase assays
H1299 cells were transiently transfected with 0.2mgo f
the various plasmids along with indicated caspase-2 pro-
moter–reporter constructs and b-galactosidase construct
to normalize for transfection eﬃciency. Luciferase assays
were performed as described (21).
RNA analysis
Total RNA was prepared from cells using TRIzol reagent
(Invitrogen) as per manufacturer’s instructions. Semi-
quantitative RT–PCR was performed using TAp73
(32 cycles), TAp63 (30), caspase-2L (33), caspase-2S (33),
caspase-8 (30), caspase-9 (30), MDM2 (30), DNp73 (34)
and gapdh (22) primers, under the following conditions:
948C for 3min, followed by cycling at 948C for 50s, 528C
for 50s and 728C for 1min. Primers used are as follows—
cas2L-for: 50GCG GCG CCG AGC GCG GGG TCT
TGG30, cas2L-rev: 50GTG GGA GGG TGT CCT GGG
AAC30, cas2S-for: 50GAT GTG GAC CAC AGT ACT
CTA G30, cas2S-rev: 50TCA TAG AGC AAG AGA
GGC GGT G30, cas8-for: 50CAA GAA CCC ATC
AAG GAT GCC TTG30, cas8-rev: 50CCA AAG TCT
GTG ATT CAC TAT CC30, cas9-for: 50TGA TCG
AGG ACA TCC AGC GG30, cas9-rev: 50GAA GCG
ACG CCG CAA CTT CTC AC30, mdm2-for: 50ATG
TGC AAT ACC AAC ATG TCT GTA CCT30, mdm2-
rev: 50AGG GGA AAT AAG TTA GCA CAA TCA TTT
GA30, TAp73-for: 50TCT GGA ACC AGA CAG CAC
CT30, TAp73-rev: 50GTG CTG GAC TGC TGG AAA
GT30, DNp73-for: 50CGC CTA CCA TGC TGT ACG
TC30, DNp73-rev: 50GTG CTG GAC TGC TGG AAA
GT30, TAp63-for: 50ACC TGA GTG ACC CCA TGT G
300, TAp63-rev: 50CGG GTG ATG GAG AGA GAG
CA300, gapdh-for: 50ACC CCT TCA TTG ACC TCA
AC30, gapdh-rev: 50CAG CGC CAG TAG AGG CAG30.
Immunoblot analysis
Cell lysates prepared in lysis buﬀer containing 0.5%
Nonidet P-40 or luciferase extracts were separated on
SDS–polyacrylamide gels and western blotted using anti-
p73 (ER15, Oncogene, Cambridge, MA, USA), anti-actin
(Sigma, St Louis, MO, USA), anti-Sp-1, anti-TAp63 and
anti-p53 (Santa Cruz) antibodies.
Chromatin immunoprecipitation assay
Cells were ﬁxed with 1% formaldehyde for 15min at room
temperature (RT), stopped with glycine to a ﬁnal concen-
tration of 125mM for 15min. Treated cells were then
washed twice with PBS and once with KM buﬀer
(pH 6.8, 10mM NaCl, 1.5mM MgCl2, 1mM EGTA,
5mM dithiothreitol, 10% glycerol, 10mM MOPS), at
10min interval. Cells were then lysed for 30min using
4ml KM buﬀer+1% NP40+protease inhibitors at 48C
and further incubated in 2.7ml 5M NaCl for 60min at
48C. Lysates were collected with TE buﬀer and sonicated
with VCX130PB (Jencons, Bridgeville, PA, USA) ﬁve
times for 10s each, with about 10min intervals on ice,
centrifuged at 13000r.p.m. at 48C for 30min and super-
natant was collected. A total of 400ml of supernatant was
used for immunoprecipitation with 10ml of anti-p73
(ER15) or anti-HA (Santa Cruz) antibodies for 2h at
48C. 1ml of Dynabeads Protein A and G (Invitrogen)
were added for a further 2h. Immune complexes were
then washed with 2 RIPA buﬀer, 1 HS buﬀer (0.1%
SDS, 1% Triton-X, 2mM EDTA, 20mM Tris–HCl, pH
8, 500mM NaCl), 1 LS buﬀer (0.1% SDS, 1% Triton-X,
2mM EDTA, 20mM Tris–HCl, pH 8, 150mM NaCl),
1 0.25M LiCl buﬀer, 1 0.5M LiCl buﬀer at 378C for
10min, followed by 2  RIPA buﬀer, 2  TE buﬀer. DNA/
protein complex was eluted with 100ml of TE buﬀer con-
taining 1% SDS and was then reverse cross-linked by
200mM NaCl at 658C for 4h, followed by proteinase
K treatment (500mg/ml) at 558C for 2h. DNA fragments
were isolated using Qiagen PCR puriﬁcation kit. PCR was
performed using Taq polymerase (Qiagen) in a 50ml solu-
tion as follows: 5ml of DNA, 1ml each of 10pmol/mlo f
primers, 1ml of 10mM dNTPs, 5mlo f1 0  buﬀer and
0.4ml of Taq polymerase. PCR conditions are as follows:
Caspase-2S promoter containing the 18bp site ! 958C—
3min, 508C—1min, 728C—30s, 39 using caspase-2SRE-
for: 50GGA CGC CCG CCC GAG CCG CTC30 and cas-
pase-2SRE-rev: 50AGT CTT TTC CCA CGA GAG AGA
CAA GGC C30 (100bp); non-speciﬁc site on Caspase-2S
promoter using non-speciﬁc-for: 50GGAATTGTGTGCT
GCGGCTG30 and non-speciﬁc-rev: 50CGCAGAGCTC
TAGCGGCGGC30 (400bp).
GST protein purification andin vitro DNA/protein
binding assay
TAp73a, TAp73b, DNp73b and p53 were cloned into
pGEX4T-1 (Pharmacia Biotech, GE, Princeton, NJ,
USA) to generate GST-73a, GST-73b, GSTDNp73b and
GST-p53 fusion proteins. These plasmids were trans-
formed into BL21 Escherichia coli and cultured in 200ml
LB broth for 4–5h, until OD600=0.5. 1mM of IPTG
was then added to the cultures and further cultured at
378C for 4h. The cultures were harvested and washed in
PBS, and then lysed by sonication at rating 3, 30s pulse,
30s interval, 10  and the lysate was collected by centrifu-
gation. The lysates were incubated with gluthatione beads
for 2h at 48C. The beads were then washed several times in
PBS and bound GST fusion proteins eluted with glu-
tathione elution buﬀer (10mM Tris, pH 8, 5mM glu-
tathione). A 18bp TAp73b recognition site on caspase-2S
promoter containing oligonucleotides, 50GAC GCC
CGC CCG AGC CGC TCC GAG30, was synthesized
with 50 biotin label on both strands. The biotin-labelled
recognition sequence was then attached to avidin-
conjugated sepharose beads (Invitrogen). Puriﬁed GST
4500 Nucleic Acids Research, 2008, Vol. 36, No. 13proteins diluted in RIPA buﬀer (0.1% SDS, 1% Triton-X,
2mM EDTA, 20mM Tris–HCl, pH 8, 150mMNaCl) were
then incubated with the recognition sequence attached
beads for 2h at 48C. After incubation, the mix was
washed six times with RIPA buﬀer. After the last wash,
30ml of protein loading buﬀer was added to the beads and
boiled for 5min before loading onto SDS–acrylamide gel
for separation.
RESULTS
TAp73b, butnot TAp73a,p53 or TAp63, induces
caspase-2S expression
We ﬁrst evaluated if p73 can transcriptionally regulate any
of the initiator caspases. TAp73b was ectopically expressed
in p53 null H1299 cells and the levels of caspase-2,- 8 and -9
mRNA were determined by semi-quantitative RT–PCR.
Although none of the full-length initiator caspases were
up-regulated by TAp73b over-expression, the short iso-
form of the caspase-2, caspase-2S, was signiﬁcantly
up-regulated (Figure 1A). Unfortunately, we were unable
to detect endogenous caspase-2S protein levels, as it is gen-
erated from a short-lived mRNA and hence, not easily
detectable under these conditions (data not shown) (30).
Nonetheless, we evaluated if this increase in caspase-2S
was speciﬁc to TAp73b over-expression by expressing the
other p53 family members. Surprisingly, we found that
only TAp73b, but not p53, TAp73a, TAp63a or TAp63b
wasabletoinducetheexpressionofcaspase-2S(Figure1B).
ItisnoteworthythatTAp73aandbothTAp63aorTAp63b
were unable to activate caspase-2S, though they were cap-
able of activating Mdm2, suggesting that this induction is
speciﬁc to the TAp73b form of TAp73.
Both TAp73b and DNp73b activate the caspase-2S
promoter
As TAp73b expression led to an increase in the steady-state
levels of caspase-2S mRNA, we ascertained if this was due
to transcriptional activation of the caspase-2S promoter.
To this end, we utilized several caspase-2 promoter-lucifer-
asereporterconstructsdescribedinourearlierstudy,which
revealed that caspase-2S can be transcribed from an alter-
nate promoter within intron 1 of the caspase-2 gene (28)
(Figure 2A, left panel). Expectedly, TAp73b expression led
to a signiﬁcant increase in the reporter activity from the
construct containing only caspase-2S promoter located
within intron 1 (Del 4), but not from the construct contain-
ing full-length caspase-2L promoter (PCM2) (Figure 2A,
right panel). TAp73b was also unable to eﬀectively activate
luciferase activity from the sequentially deleted promoter
constructs containing the caspase-2L exon 1 and intron 1
(Del 1, Del 2 and Del 3) (28), despite all of them containing
the caspase-2S promoter located in intron 1 (Figure 2A,
right panel). This suggests that there may be negative
regulatory elements in exon 1, preventing TAp73b-
mediated caspase-2 activation. Nonetheless, these data
conﬁrms our initial ﬁnding that TAp73b induces caspase-
2s expression by transcriptionally activating its promoter.
Analysis using the other p53 family members conﬁrmed
our earlier RT–PCR data that only TAp73b, but not p53,
TAp63a or TAp63b is able to eﬀectively activate the
caspase-2 promoter (Del4), though all proteins were
approximately equally expressed (Figure 2B). Next, we
evaluated if the DNA-binding ability and TA domain of
TAp73b are required to activate the Del4 reporter con-
struct by utilizing the TAp73b-R292H, which has a
point mutation in the DNA-binding domain and hence,
defective in its ability to speciﬁcally bind DNA, and the
DNp73b that lacks the TA domain. This analysis revealed
A
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caspase-9
gapdh
caspase-2L
caspase-8
caspase-2S
TAp73
B
p53
pcDNA
TAp73α
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TAp63
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mdm2
gapdh
Figure 1. TAp73b, but not p53, TAp73a, TAp63a or TAp63b, induce
caspase-2S expression. (A) TAp73b expression induces the up-regulation
of caspase-2S but not other caspase transcripts. The pcDNA and
TAp73 expression constructs were transfected into H1299 cells for
36h before RNA extraction and cDNA synthesis. Semi-quantitative
RT–PCR was performed for caspase-2L, caspase-8, caspase-9 and cas-
pase-2S transcripts. (B) The pcDNA, p53, TAp63a, TAp63b, TAp73a
and TAp73b expression constructs were transfected into H1299 cells
similarly and expression of caspase-2L and caspase-2S transcripts were
analysed. Mdm2 was used as a positive control and the expression of
the transfected p53 family members is shown.
Nucleic Acids Research, 2008, Vol. 36, No. 13 4501that the DNA-binding ability of TAp73b is essential to
activate caspase-2S promoter, as the TAp73b-R292H
mutant was almost completely defective in transactiva-
tion, though being expressed eﬃciently (Figure 2C).
However, unexpectedly, we found that DNp73b without
the TA domain was able to transactivate the caspase-2S
promoter, and mutation in the DNA-binding domain of
DNp73b abrogated this eﬀect (Figure 2C). These results
together indicate that TAp73b and DNp73b are speciﬁ-
cally capable of transcriptionally activating the caspase-2S
promoter, though the NH2-terminal TA domain is dispen-
sable for this process.
A unique element in thecaspase-2S promoter is required
foractivation by p73b
We next characterized the caspase-2S promoter to deﬁne
the minimal DNA sequence required for activation, by
making sequential deletions of the Del 4 construct
(Figure 3A). We made the assumption that the essential
Figure 2. Activation of caspase-2S promoter by TAp73b and DNp73b.( A) Left panel shows the schematic of the caspase-2S promoter-luciferase
constructs used in the study. Curved arrows represent the TATA box. Exon 1 of caspase-2S and caspase-2L are shown. These constructs were
transfected together with TAp73b and b-gal plasmid into H1299 cells for 24h. The cultures were then lysed and used for luciferase assays (right
panel). (B) Activation of Del 4 reporter construct is speciﬁc only to TAp73b. The indicated reporter constructs were transfected together with either
of the following: p53, TAp63a, TAp63b, TAp73a and TAp73b, together with the b-gal plasmid into H1299 cells for 24h, prior to analysis of
luciferase activity (left panel). Right panel shows immunoblot analysis of the expression of the transfected plasmids. (C) DNA-binding ability of p73b
is essential for induction of Del4 promoter. Del4 reporter constructs were transfected together with either TAp73b or TAp73b-292, or DNp73b or
DNp73b-292 together with b-gal plasmid into H1299 cells, prior to analysis of luciferase activity (left panel). Right panel shows immunoblot analysis
of the expression of the transfected plasmids. All luciferase assays were repeated at least thrice, each time in duplicates. The graphs are representation
of average SED.
4502 Nucleic Acids Research, 2008, Vol. 36, No. 13site should lie upstream of the TATA box (Supplementary
Figure 1A, indicated in bold), and hence, made deletions
starting from the 50-end of Del4 towards the 30-end till
prior to the TATA box (Figures 3A and Supplementary
Figure 1A). These constructs, termed Del 4.1, 4.2 and 4.3,
were co-transfected together with TAp73b to analyse
their activity. Surprisingly, TAp73b was unable to activate
any of these deletions constructs, when compared to the
parent Del4 promoter (Figure 3B), suggesting that the site
that is required for TAp73b to activate the caspase-2S
promoter probably lies upstream of Del 4.1. The fragment
between Del 4 and Del 4.1 is only about 18-bp long and
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Figure 3. Characterization of DNA elements required for activation of caspase-2S promoter by p73. (A) Schematic shows the deletion constructs
made sequentially using Del 4. (B) The sequentially truncated Del4 constructs were transfected together with TAp73b and b-gal into H1299 cells for
24h, prior to luciferase analysis. (C) Del4 and Del4-Sp-1 mutant reporter constructs were transfected together with TAp73b or Sp-1, alone or in
combination, into H1299 cells for luciferase analysis. The fold induction of luciferase activity was derived by dividing the values obtained with the
respective constructs with that of pcDNA-transfected samples. Right panel shows immunoblot analysis of the expression of the transfected plasmids.
(D) Knockdown of Sp-1 does not signiﬁcantly aﬀect the activation of Del4 promoter by TAp73b. Control or Sp-1 siRNA were transfected into
H1299 for 24h prior to transfection of the Del4, TAp73b and b-gal constructs for luciferase analysis. Fold induction of luciferase activity is shown.
Right panel shows eﬃciency of Sp-1 knockdown by immunoblotting. All luciferase assays were repeated at least thrice, each time in duplicates. The
graphs are representation of average SED.
Nucleic Acids Research, 2008, Vol. 36, No. 13 4503contains a GC-rich box to which the Sp-1 transcription
factor could potentially bind (31) (Supplementary
Figure 1B). To test if the Sp-1-binding site is required
for TAp73b-mediated activation, we generated a mutant
construct in which the Sp-1 site was mutated by site-direc-
ted mutagenesis (Supplementary Figure 1B). Luciferase
assays indicted that though there was a slight decrease in
total activity, TAp73b was still capable of consistently
activating the Del4-Sp-1 mutant construct, and the fold
of activation of the promoter–luciferase activity was sig-
niﬁcant for both the wild-type and Sp-1-mutant promoters
(Del4 versus Sp-1-mut: 83.0 versus 62.0) (Figure 3C,
left panel). To evaluate if Sp-1 would aﬀect TAp73b-
mediated caspase-2S promoter activation, we co-trans-
fected Sp-1 cDNA with TAp73b cDNA. Expression of
Sp-1 alone led to a marginal activation of the caspase-2S
promoter, and this eﬀect was abrogated when the Sp-1 site
was mutated (Del4 versus Sp-1-mut: 8.0 versus 3.0)
(Figure 3C, left panel). Co-expression of TAp73b with
Sp-1 resulted in a decrease in the TA potential compared
to when TAp73b was expressed alone (Del4 versus Sp-1-
mut: 40.0 versus 44.0) (Figure 3C, left panel). Nonetheless,
the combined eﬀect of TAp73b and Sp-1 was not aﬀected
by mutation of the Sp-1-binding site. Immunoblot analysis
indicated that both the levels of Sp-1 and TAp73 were
consistently reduced when co-expressed, suggesting other
inter-regulation between them (Figure 3C, right panel).
These data together suggest that the Sp-1-binding site
may not be crucial for p73 to activate caspase-2S, and
that Sp-1 may not have a signiﬁcant role in regulating
TAp73b-mediated caspase-2S promoter activation.
To further determine if Sp-1 is required for TAp73b-
dependent activation of the caspase-2S promoter, we
silenced its expression using Sp-1-speciﬁc siRNA 24h
prior to luciferase assays using the Del4 construct. As
seen in Figure 3D, silencing of Sp-1 expression did not
aﬀect the induction of Del4 activity by TAp73b, and the
ratio of activation was comparable between control and
Sp-1 siRNA treatment (control versus Sp-1 siRNA: 26.5
versus 33.5). These results therefore together suggest that
the 18-bp element within the GC-rich box in caspase-2S
promoter is required for TAp73b-mediated expression,
which is probably independent of Sp-1.
TAp73b and DNp73b bind to the unique site
in vitro and in vivo
Since both TAp73b and DNp73b activated the caspase-2S
promoter through their DNA-binding domains, we tested
if they can directly bind to the 18-bp element identiﬁed as
being important for caspase-2S promoter activation by
TAp73b. In the ﬁrst instance, in vitro DNA-binding
assays were performed using bacterially puriﬁed GST-
TAp73b, GST-TAp73a, GST-DN73b and GST-p53, and
a biotin-labeled 24-bp oligonucleotide encompassing the
18-bp element. Incubation of GST proteins and oligonu-
cleotides together with avidin-conjugated agarose beads,
followed by washing to remove excess unbound proteins
and subsequent immunoblotting revealed that only
TAp73b and DN73b, but not TAp73a or p53, could
bind to the beads containing the 18-bp DNA sequence
(Figure 4A, compare lanes 1 to 3). This binding, though
weak, was reproducible. To conﬁrm this result, we
attempted to detect endogenous binding of TAp73b and
DNp73b to the caspase-2S promoter in vivo, using chro-
matin immunoprecipitation (ChIP) assays. We used two
cell lines for this purpose: the Saos2-TAp73b inducible
cells and the human SH-SY5Y neuroblastoma cell line
stably expressing DNp73b. The caspase-2S mRNA expres-
sion was up-regulated upon TAp73b induction in Saos2-
TAp73b cells and was higher in SH-SY5Y cells stably
expressing DNp73b compared to their pcDNA-expressing
control counterparts (Figure 4B and C). There were no
diﬀerences in the levels of caspase-2L in both cases
(Figure 4B and C). Immunoprecipitation with anti-p73
or the irrelevant anti-HA antibodies was followed by
PCR ampliﬁcation of the region ﬂanking the 18-bp site
on the caspase-2S promoter (indicated as Casp-2S)o ra n
irrelevant site away from this region. As shown in
Figure 4D, strong and speciﬁc binding of TAp73 was
noted on the region surrounding the 18-bp element but
not on the non-speciﬁc site in Saos2-TAp73b cells. Both
these sites were ampliﬁable from crude lysates prior to
immunoprecipitation, indicating the presence of these
DNA fragments in the lysates (input). Similarly, ChIP
analysis using the SH-SY5Y cells indicated a PCR product
ampliﬁed speciﬁcally in DNp73b-expressing cells and not
in pcDNA cells with the anti-p73 antibody, which was also
not signiﬁcantly present in anti-HA immunoprecipitates
(Figure 4E, upper panel). No PCR product was ampliﬁed
from the non-speciﬁc site on the caspase-2S promoter
(Figure 4E, lower panel). These data together suggest
that TAp73b and DNp73b can bind to the caspase-2S
promoter containing the 18-bp site identiﬁed by the lucif-
erase assays, both in vitro and in vivo, and highlight that
the lack of the TA domain does not aﬀect the binding of
DNp73b to DNA sequences.
Over-expression of DNp73bprotects cellsfrom cell death
through caspase-2S activation
Over-expression of caspase-2S has been shown to protect
cells from cell death induced by serum deprivation (27).
Hence, we tested if the SH-SY5Y-DNp73b cells, which
express higher levels of caspase-2S mRNA, are also more
resistant to serum deprivation-induced cell death. Serum
deprivation of both SH-SY5Y-pcDNA and SH-SY5Y-
DNp73b cells followed by analysis of DNA content to
monitor the sub-G1 population—which reﬂects apoptotic
cells—indicated that there was less cell death in the
SH-SY5Y-DNp73b cells (% sub-G1 cells ! pcDNA
versus DNp73b cells: 28.9 versus 16.0 [day2]; 31.0 versus
20.0 [day3]) (Figure 5A and B). Similarly, though treat-
ment with another cellular insult, cisplatin, resulted in an
increase in cell death of pcDNA cells, there was no sig-
niﬁcant death in DNp73b cells (% dead cells !  /+
cisplatin—pcDNA versus DNp73b cells: 8.0/20.0 versus
5.0/4.8) (Figure 5C).
In order to verify if the resistance to cell death is due to
DNp73b-mediated caspase-2S activation, we silenced the
expression of the over-expressed DNp73b using p73-spe-
ciﬁc siRNA, followed by serum-starvation for up to 48h.
4504 Nucleic Acids Research, 2008, Vol. 36, No. 13Silencing of p73 resulted in a decrease in the DNp73b
levels, as expected (Figure 5D). Importantly, the levels
of caspase-2S were also reduced concomitantly
(Figure 5D), indicating that DNp73b is indeed responsible
for caspase-2S activation. Analysis of cell death revealed
that silencing DNp73b expression consistently led to an
increase in cell death, compared to control siRNA treated
cells (% dead cells upon serum-starvation: SH-SY5Y-
pCDNA cells–20.0; SH-SY5Y-DNp73b cells—control
versus p73 siRNA: 11.0 versus 16.5) (Figure 5E). These
data together indicate that expression of DNp73b, which
leads to up-regulation of caspase-2S, contributes to protec-
tion of cells against cell death induced by multiple means.
DISCUSSION
The ﬁndings presented here highlight two salient points:
that the tumour-suppressor TAp73b is able to induce the
expression of the anti-apoptotic caspase-2S, and that
DNp73b, without the NH2-terminal TA domain, is also
capable of activating caspase-2S expression. The former
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Nucleic Acids Research, 2008, Vol. 36, No. 13 4505ﬁnding, though at ﬁrst instance perplexing, is entirely
compatible with the emerging view that TAp73b may
have other roles in supporting cellular growth. The latter
ﬁnding highlight the fact that some targets can be
common to both TAp73b and DNp73b, and hence, may
explain why many human tumours co-over-express
both TAp73 and DNp73 to provide a strong survival
pressure.
It is striking that expression of the tumour-suppressor
TAp73b, which induces cell death when over-expressed
in many cellular systems, is able to transactivate the
anti-apoptotic capase-2S gene. Though loss of all p73
forms result in increased resistance to cell death (9,32),
TAp73 is over-expressed in many human cancers (6,11–
17). Intriguingly, it is to be noted that physiologically,
TAp73b transcripts are not readily detectable (33). These
mitigating reasons raise the interesting possibility that
TAp73b may have evolved to also support cellular survival
under certain conditions, such as seen in human cancers. In
support of this, we have recently shown that expression of
TAp73 can cooperate with c-Jun to activate AP-1 target
genes such as cyclinD1, and hence, promote cellular
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4506 Nucleic Acids Research, 2008, Vol. 36, No. 13survival (18). Moreover, absence of p73 led to reduced
expressionofcyclinD1anddecreasedcellularproliferation.
In addition, other groups have also raised the possibility
that TAp73 may be involved in the activation of genes that
are involved in tumourigenesis, such as b-catenin and gas-
trin (19,20). Thus, these ﬁndings together favour the argu-
ment for a contributory role of TAp73 in supporting
cellular survival, in one way by activating the expression
of capase-2S as demonstrated here.
In addition, DNp73b is the variant of p73 that is predo-
minantly expressed in the brain and sympathetic neurons
(23).Thep73
 / micedisplayseveredefectsintheirnervous
system including massive cell death, suggesting that
DNp73b plays an anti-apoptotic role in the brain (33).
Over-expression of DNp73b in sympathetic neurons was
also able to rescue cell death resulting from nerve growth
factor withdrawal (34). Similarly, caspase-2S is highly
expressed in the brain and caspase-2S has been shown to
protect cells from cell death induced by several means
(27,35). Therefore, our results that the SH-SY5Y neuro-
blastoma cells stably over-expressing DNp73b—which
express higher level of caspase-2S compared with pcDNA
expressing control cells—are resistant to cell death upon
serum starvation and cisplatin treatment are entirely con-
sistent with a protective role for DNp73b in some cellular
contexts. Importantly, reducing the exogenously expressed
DNp73b levels by gene silencing led to a decrease in cas-
pase-2S expression and a concomitant reversal of resistance
tocelldeath,suggesting thattheactivationofcaspase-2Sby
DNp73b indeed leads to protection against cell death.
However, we have not been able to speciﬁcally silence the
expression of caspase-2S in DNp73b-over-expressing cells
to demonstrate its relevance due to the sequence similarity
of caspase-2S and caspase-2L (data not shown).
Nonetheless, our data suggest that physiologically,
DNp73b may act through caspase-2S to protect neuronal
cells from cell death.
Activation of caspase-2S was found to be speciﬁc to the
p73family,butnottop53,TAp63aandTAp63bthoughall
three p53 family members share similar DNA-binding
domains and are thought to be able to activate a large
subset of p53 target genes (6,36). However, the speciﬁcity
of the p73 family could arise due to subtle diﬀerences else-
where,whichmaybemorecriticalforbindingtotheunique
site on the caspase-2S promoter, besides the common
DNA-binding domain. However, this cannot explain why
TAp73a, which also share the same DNA-binding and
other domains as TAp73b, and is over-expressed in
human cancers as TAp73b, cannot induce caspase-2S
expression. The sterile a-domain present in TAp73a but
not in TAp73b has been shown to play an inhibitory role
in TA, making TAp73a a weaker transactivator of target
genes compared to TAp73b (37,38). This could be a reason
for the inability of TAp73a to activate caspase-2S in experi-
mental conditions, though it may be able to activate cas-
pase-2S expression in vivo, in conditions where the eﬀect of
the sterile alpha motif (SAM) domain is negated by other
means. This possibility remains to be explored.
Nevertheless, the 18-bp site to which the p73 members
bind to on the caspase-2S promoter does not resemble the
p53 consensus binding site. Rather, it contains a GC box, a
putative binding site for Sp-1 transcription factor.
Mutation of the GC box and knockdown of Sp-1 expres-
sion did not signiﬁcantly aﬀect TAp73b’s ability to activate
the caspase-2S promoter, suggesting that TAp73b does not
depend on Sp-1 to activate the promoter. Moreover, com-
parison of Sp-1 and TAp73b’s ability to activate the cas-
pase-2S promoter indicated that TAp73b was a better
activator than Sp-1, which only had a marginal eﬀect,
thereby excluding any critical role for the latter in cas-
pase-2S activation. Furthermore, DNA-binding mutants
of p73 were unable to activate the caspase-2S promoter
and conversely, both in vivo ChIP experiments and
in vitro DNA-binding assays revealed that p73 was able
to bind to this DNA element, indicating that p73 can
indeed directly bind to and activate the caspase-2S promo-
ter. Whether this 18-bp element is a unique site that is of
generalutilityforactivationofp73-speciﬁc(andnotp53-or
p63-dependent) targets is yet to be explored. Overall, the
ﬁndingshighlightthespeciﬁcityofTAp73bandDNp73bin
the induction of caspase-2S expression.
The ability of both full-length TAp73b and the TA-deﬁ-
cient DNp73b to induce caspase-2S promoter activation is
also surprising, but highlights that the DNp73 form may
have the ability to activate target genes. There are not
many reports that have highlighted that both of these
forms can activate classical p53/p73 target genes, as
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Figure 5. Continued.
Nucleic Acids Research, 2008, Vol. 36, No. 13 4507traditionally, it has been thought that the TA domain is
essential for transcription factors to recruit co-factors for
transactivation of target genes. Therefore, the ﬁndings
presented here suggest that DNp73b has unique transac-
tivation ability, besides its role as a dominant-negative
protein to inhibit p73 and p53 function. Two similar
examples were reported, whereby DNp73a was shown to
activate the expression of EGR1 and CDC6, and DNp73b
was shown to activate classical p53 target genes (5,39).
Mechanistically, how this occurs is unclear. It was specu-
lated that the presence of a secondary TA domain in
DNp73, which encompass the 13 unique residues at the
NH2-terminus together with the PXXP motifs, may form
a TA domain responsible for the activity of DNp73 (5).
Alternatively, DNp73b may recruit other transcription
factors to activate the capase-2S promoter activity.
Whatever the mechanism may be, it is evident that
DNp73 has the ability to activate target genes, which are
unique and does not fall into to the classical ‘p53-target’
gene group.
Another noteworthy point is that both TAp73b and
DNp73b were not able to activate the expression from
the full-length caspase-2 promoter. Only after truncating
the promoter to retain the caspase-2S promoter region
speciﬁcally did we see an increase in promoter activity,
suggesting the existence of repressor elements that may
interfere with the induction of caspase-2S by p73b.
Moreover, we cannot exclude the possibility that usage
of one promoter may be at the expense of the other,
though this needs further investigation. This indicates
that speciﬁc conditions may be required for the
induction of caspase-2S by p73b in vivo in the physiologi-
cal setting.
In conclusion, the data presented here provide evidence
for the activation of the anti-apoptotic caspase-2S by both
the tumour-suppressive TAp73b and the anti-apoptotic
DNp73b, which could be yet another mechanism to pro-
mote cellular survival in tumor settings where both p73
forms are over-expressed.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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